Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BWT7
UPID:
CAR10_HUMAN
Alternative names:
CARD-containing MAGUK protein 3
Alternative UPACC:
Q9BWT7; Q14CQ8; Q5TFG6; Q8NC81; Q9UGR5; Q9UGR6; Q9Y3H0
Background:
Caspase recruitment domain-containing protein 10, also known as CARD-containing MAGUK protein 3, plays a pivotal role in immune response regulation. It acts as a scaffold protein, crucial for the activation of NF-kappa-B via BCL10 or EGFR, signaling pathways that are essential for immune cell activation and inflammatory responses.
Therapeutic significance:
The protein is linked to Immunodeficiency 89 and autoimmunity, a disorder marked by recurrent infections, allergies, microcytic anemia, and Crohn disease. This association highlights its potential as a target for therapeutic intervention in immune-related disorders.